...
首页> 外文期刊>Human Pathology >Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study.
【24h】

Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study.

机译:糖皮质激素受体在肾细胞肿瘤中的表达:免疫组织化学和定量逆转录酶聚合酶链反应研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Glucocorticoid receptors mediate the action of steroid hormones in a variety of tissues, including the kidney. Our goal was to determine the expression pattern and prognostic significance of glucocorticoid receptor in renal cell neoplasms. Paraffin-embedded microarrays from 200 patients with RCNs including 147 clear cell renal cell carcinomas, 23 papillary, 16 chromophobe renal cell carcinoma, and 14 oncocytomas were analyzed for glucocorticoid receptor expression by immunohistochemistry. Glucocorticoid receptor expression was also quantitated by real-time reverse transcriptase polymerase chain reaction in 45 cases (33 clear cell renal cell carcinomas, 5 chromophobe renal cell carcinomas, and 3 oncocytomas). Strong nuclear glucocorticoid receptor expression was present in normal glomeruli and in the proximal convoluted tubules. Nuclear glucocorticoid receptor expression was found in most clear cell renal cell carcinomas (66%), in 26% of papillary renal cell carcinomas, and in only 6% of chromophobe renal cell carcinomas and 14% of oncocytoma (P < .005). Within the clear cell renal cell carcinoma group, most positive cases (87%) demonstrated strong immunoreactivity (2+ and 3+), whereas only 1 papillary renal cell carcinoma, 1 chromophobe renal cell carcinoma, and none of the oncocytomas showed strong expression. Glucocorticoid receptor alpha messenger RNA expression was significantly higher in clear cell renal cell carcinoma than in chromophobe renal cell carcinoma, oncocytoma, or in the normal kidney. Significantly more frequent glucocorticoid receptor expression was associated with tumors of low nuclear grade (Fuhrman grade 1 and 2) and low stage (stages 1 and 2; P = .0068 and P = .0002). Survival analysis revealed a significant direct correlation between glucocorticoid receptor expression and overall survival in clear cell renal cell carcinoma (P = .01). In summary, strong glucocorticoid receptor expression was most commonly seen in clear cell renal cell carcinoma and only rarely seen in other subtypes. The glucocorticoid receptor expression pattern in RCNs seems to reflect the histogenetic origin of clear cell renal cell carcinoma from the proximal nephron. Finally, glucocorticoid receptor expression proved to be a marker of less aggressive behavior in clear cell renal cell carcinoma.
机译:糖皮质激素受体介导类固醇激素在包括肾脏在内的多种组织中的作用。我们的目标是确定糖皮质激素受体在肾细胞肿瘤中的表达模式和预后意义。通过免疫组织化学分析了来自200例RCN的石蜡包埋的微阵列,包括147例透明细胞肾细胞癌,23例乳头状癌,16例发色肾细胞癌和14例细胞瘤。还通过实时逆转录酶聚合酶链反应对45例(33例透明细胞肾细胞癌,5例发色肾细胞癌和3例肿瘤细胞瘤)中的糖皮质激素受体表达进行了定量。正常肾小球和近曲小管中存在强核糖皮质激素受体表达。在大多数透明细胞肾细胞癌(66%),26%乳头状肾细胞癌,仅6%的发色肾细胞癌和14%的肿瘤细胞瘤中发现了核糖皮质激素受体的表达(P <.005)。在透明细胞肾细胞癌组中,大多数阳性病例(87%)表现出较强的免疫反应性(2+和3+),而只有1例乳头状肾细胞癌,1例发色肾细胞癌,并且没有一个瘤细胞瘤表现出强表达。透明细胞肾细胞癌中糖皮质激素受体α信使RNA的表达明显高于发色肾细胞癌,肿瘤细胞瘤或正常肾脏中的糖皮质激素受体α信使RNA表达。糖皮质激素受体的表达更为频繁与低核级(Fuhrman 1级和2级)和低分期(1级和2级; P = .0068和P = .0002)的肿瘤有关。生存分析显示,在透明细胞肾细胞癌中,糖皮质激素受体的表达与总生存之间存在显着的直接相关性(P = 0.01)。总之,强糖皮质激素受体表达最常见于透明细胞肾细胞癌,而很少见于其他亚型。 RCNs中糖皮质激素受体的表达模式似乎反映了近端肾单位清除细胞肾细胞癌的组织遗传学起源。最后,糖皮质激素受体表达被证明是透明细胞肾细胞癌中侵袭性较低的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号